

# Gas-Phase Dissociation of Oligoribonucleotides and their Analogs Studied by Electrospray Ionization Tandem Mass Spectrometry

Jan M. Tromp and Stefan Schürch

Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland

Oligoribonucleotides (RNA) and modified oligonucleotides were subjected to low-energy collision-induced dissociation in a hybrid quadrupole time-of-flight mass spectrometer to investigate their fragmentation pathways. Only very restricted data are available on gas-phase dissociation of oligoribonucleotides and their analogs and the fundamental mechanistic aspects still need to be defined to develop mass spectrometry-based protocols for sequence identification. Such methods are needed, because chemically modified oligonucleotides can not be submitted to standard sequencing protocols.

In contrast to the dissociation of DNA, dissociation of RNA was found to be independent of nucleobase loss and it is characterized by cleavage of the 5'-P—O bond, resulting in the formation of c- and their complementary y-type ions. To evaluate the influence of different 2'-substituents, several modified tetra-ribonucleotides were analyzed. Oligoribonucleotides incorporating a 2'-methoxy-ribose or a 2'-fluoro-ribose show fragmentation that does not exhibit any preferred dissociation pathway because all different types of fragment ions are generated with comparable abundance. To analyze the role of the nucleobases in the fragmentation of the phosphodiester backbone, an oligonucleotide lacking the nucleobase at one position has been studied. Experiments indicated that the dissociation mechanism of RNA is not influenced by the nucleobase, thus, supporting a mechanism where dissociation is initiated by formation of an intramolecular cyclic transition state with the 2'-hydroxyl proton bridged to the 5'-phosphate oxygen. (J Am Soc Mass Spectrom 2005, 16, 1262–1268) © 2005 American Society for Mass Spectrometry

Antisense oligonucleotides are nucleic acids of about 12 to 20 nucleobases, which are designed to hybridize to a complementary messenger RNA (mRNA) sequence, thus, inhibiting gene expression [1-3]. Therefore, they are of great interest in human cancer therapy and for diagnostic applications. Besides the high binding specificity of antisense oligonucleotides to their target mRNA, affinity, bioavailability, and biostability are of foremost importance. However, a major drawback of the application of unmodified phosphodiester DNA or RNA oligonucleotides is that these structures are subjected to rapid nuclease degradation under physiological conditions. To improve these factors, oligonucleotide analogs, exhibiting chemical modifications of the phosphodiester backbone, of the ribose, and, to a limited extent, also of the nucleobases, are evaluated.

Mechanisms of inhibition of gene expression by antisense oligonucleotides involve mRNA degrading

enzymes such as RNase H, blockade of translation initiation, or modulation of splicing [4-7]. These mechanisms allow the application of new chemical modifications to increase the binding affinity and the nuclease resistance. Possible positions of the modifications are the phosphodiester backbone, the sugar unit and the nucleobases. Introduction of a phosphorothioate backbone increases nuclease resistance of antisense oligonucleotides and simultaneously serves as a very efficient substrate for mRNA degrading enzymes [6-9]. Unfortunately, such modification reduces the binding affinity to the complementary mRNA. Thus, further chemical modifications (e.g., derivatization of the ribose 2'-position by electronegative substituents) have been introduced to increase the affinity and to further enhance their nuclease resistance [10]. However, most of these highly modified oligonucleotide analogs do not support enzymatic activity and alternative mechanisms not relying on RNase H activity are required.

Apart from the development of appropriate synthetic methodologies, evaluation of oligonucleotide analogs is among the main focuses of antisense research. Evaluation of antisense oligonucleotides for therapeutic and diagnostic applications requires suitable analytical

Published online June 23, 2005

Address reprint requests to Dr. Stefan Schürch, Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland. E-mail: stefan.schuerch@ioc.unibe.ch

tools for sequence determination and detailed structural elucidation. Because of the presence of unnatural structural elements, the classical sequencing techniques [11, 12] are likely to fail and alternative approaches for rapid and accurate sequencing of chemically modified oligonucleotides have to be developed. Tandem mass spectrometry is a highly attractive candidate for this task, because it is capable of providing the high degree of structural information required.

Within the past decade, detailed mechanistic data on the dissociation of unmodified oligodeoxyribonucleotides (DNA) in gas-phase have been provided. The loss of the nucleobase was found to be the initial dissociation step, leading to the subsequent cleavage of the 3'-C—O bond, thus, resulting in the formation of the generally abundant [a-B] and w ions. Several different mechanisms have been proposed and evaluated to explain the formation of the DNA typical [a-B] and w fragment ions [13–15] and the generally applied nomenclature of oligonucleotide fragments was proposed by McLuckey et al. in 1992 [16]. On the other hand, very limited data are available on the dissociation of RNA and oligonucleotide analogs.

Because of their use in antisense applications, methylphosphonate and phosphorothioate oligonucleotides are among the most widely studied analogs. Oligonucleotides with a methylphosphonate backbone have been investigated to study the effect of backbone charge on backbone dissociation and to trace the origin of the proton transferred to the nucleobase as the initial step of DNA dissociation [17, 18]. Oligonucleotides based on the phosphorothioate backbone are highly promising compounds for therapeutic antisense applications. The first of these antisense oligonucleotides was admitted to market in 1998 and further RNase H activating phosphorothioate oligonucleotides are currently in various stages of clinical trial [3, 19–21]. Investigation of the dissociation pattern of phosphorothioate, and phosphodiester oligodeoxyribonucleotides in gas-phase revealed that both backbone modifications yield the same types of fragment ions [22, 23].

Information on the fragmentation mechanism of RNA in gas-phase is rare. The few reports found indicate that dissociation of RNA clearly differs from the dissociation of DNA. The preferred cleavage site of RNA is the 5'-P—O bond, resulting in the formation of c- and y-type ions [24–26]. It has been shown that oligoribonucleotides possess higher gas-phase stability than oligodeoxyribonucleotides because of stabilization of the *N*-glycosidic bond by the 2'-OH substituent [10, 27]. Unlike dissociation of DNA, backbone dissociation of RNA is independent of nucleobase loss. Collision-induced dissociation (CID) of mixed sequence DNA/RNA oligonucleotides demonstrated that backbone cleavage is controlled locally and influenced by the type of adjacent ribose 2'-substituent. No evidence for any remotely located group affecting the dissociation was found and a fragmentation mechanism was proposed [26]. Furthermore, the fragmentation patterns of differ-

ent 2'-ribose-modified oligonucleotides have been described without focusing on the mechanistic aspects of gas-phase dissociation [23, 28]. Reports specifically focusing on the dissociation mechanisms of 2'-modified oligonucleotides and their gas-phase stability are missing completely.

In this article we report on the dissociation of selected nucleobase- or 2'-ribose-modified oligonucleotides. To gain insight into the fragmentation mechanism of oligoribonucleotides and for better understanding of the influence of different 2'-substituents, a number of selectively modified oligoribonucleotides have been investigated by electrospray tandem mass spectrometry on a hybrid quadrupole time-of-flight mass spectrometer.

## Experimental

### Sample Preparation

RP-HPLC (reversed-phase high performance liquid chromatography) purified oligonucleotides were obtained from TriLink BioTechnologies (San Diego, CA) and Microsynth (Balgach, Switzerland). The lyophilized oligonucleotides were dissolved in a mixture of water/ acetonitrile/triethylamine (49/49/2) resulting in a final oligonucleotide concentration of about 30 pmol/ $\mu$ L. Typically, a sample volume of 3  $\mu$ L was used for each analysis.


### Mass Spectrometry

All experiments were performed on an Applied Biosystems/MDS Sciex QStar Pulsar hybrid quadrupole time-of-flight mass spectrometer (Sciex, Concord, Canada), equipped with a nanoelectrospray ion source (Protana, Odense, Denmark). Oligonucleotides were analyzed in the negative-ion mode with a potential of  $-900$  V applied to the nanospray needle. Nitrogen was used as the curtain gas.

Tandem mass spectrometric experiments were performed with precursor ions selected within a window of  $\pm 1.5$  *m/z* units. CID was performed with collision energies in the range of 10–35 eV using nitrogen as the collision gas. The time-of-flight analyzer was tuned for an average mass resolving power of 10,000 (full width at half maximum) and calibrated externally using a mixture of cesium iodide and taurocholic acid. Calibration was performed before each series of experiments or at least once a day. The Applied Biosystems Analyst QS software package was used for data processing. Product ion spectra of tetranucleotides are based on the doubly deprotonated precursor ions.

## Results and Discussion

A partial section of the product ion spectra of the tetranucleotides d(TATG) and UAUU is shown in Figure 1. It shows the unique fragment ion pattern of RNA, which clearly differs from the pattern of DNA. The



**Figure 1.** Comparison of the product ion spectra of DNA and RNA. (a) Product ion spectrum of the deoxyribonucleotide d(TATG), obtained by dissociation of the  $[M-2H]^{2-}$  precursor ion with  $m/z$  593.13. The abundant  $w_2$  ion ( $m/z$  650.13) is a result of the cleavage of the 3'-C—O bond, which is initiated by nucleobase loss. (b) The product ion spectrum of the  $[M-2H]^{2-}$  precursor ion of the tetranucleotide UAUU ( $m/z$  591.63) predominantly shows the RNA characteristic  $y_2$  and  $c_2$  ions with  $m/z$  549.13 and 634.12, respectively. Other fragments, because of backbone cleavage, are of significantly lower intensity.

product ion spectrum of the doubly deprotonated tetra-deoxyribonucleotide d(TATG) with  $m/z$  593.13 is shown in Figure 1a. The spectrum is characterized by the abundant DNA typical  $w_1$ ,  $w_2$ , and  $w_3$  fragment ions with  $m/z$  346.07, 650.13, and 963.20, respectively, generated by cleavage of the 3'-C—O bonds. The complementary [a-B]-type ions and additional fragments due to backbone cleavage at alternative positions and nucleobase loss are observed with reduced abundance. On the other hand, the product ion spectrum of the tetranucleotide UAUU ( $[M-2H]^{2-}$ ,  $m/z$  591.63) shows abundant  $y$ - and  $c$ -type ions (Figure 1b). Most of the theoretically possible fragment ions originating

from backbone cleavage can be found in the spectrum. The  $y_2$  ion ( $m/z$  549.13) exhibits about a fourfold higher abundance than the other 3'-terminal ions ( $w_2$ ,  $x_2$ , and  $z_2$ ). Likewise, the abundance of the  $c_2$  ion ( $m/z$  634.12) is about three times higher, compared with the alternative 5'-terminal fragment ions ( $a_2$ ,  $b_2$ , and  $d_2$ ). The observed formation of  $c$ - and their complementary  $y$ -type ions confirms the 5'-P—O bond as the preferred cleavage site within the RNA backbone. RNA typical behavior was also found for the first and third phosphodiester group of the tetranucleotide (data not shown).


The different fragment ion patterns observed for DNA and RNA must be related to the presence of the altered 2'-substituent. The electronegative hydroxyl group of RNA plays a key role in the dissociation mechanism, because it effectively stabilizes the  $N$ -glycosidic bond. The inductive effect of such a strong electron-withdrawing group impedes formation of the carbocation at the 1'-position [10], thus, rendering nucleobase loss less prominent. Furthermore, the availability of the additional proton in the vicinity of the phosphodiester group provides alternative pathways for backbone cleavage.

To obtain mechanistic data on the gas-phase dissociation of RNA and to evaluate the influence of different 2'-substituents on the dissociation and stability of the  $N$ -glycosidic bond, a number of tetranucleotides bearing a single modified nucleotide have been studied. Modifications include 2'-methoxy and 2'-fluoro substituents at the 2'-position of the second nucleotide, and a deoxynucleotide lacking the nucleobase (dSpacer) as the third building block within the sequence (Scheme 1). Thus, the influence of the modifications on the second phosphodiester group can be observed.

Tetramers were chosen for this study because they can be dissociated efficiently under low-energy CID conditions, and the length of the nucleotide sequences is still sufficient to study the effect of selected local modifications on backbone dissociation. Hydrogen/deuterium exchange experiments, which are often used for localizing the origin of protons transferred on dissociation reactions, do not provide conclusive information on the dissociation of RNA, because 2'-hydroxyl protons, remaining phosphate protons on the backbone, and amino protons of the nucleobases would be exchanged.

Compared with unmodified RNA, oligoribonucleotides with a 2'-methoxy-adenosine as the second nucleotide exhibits a different fragmentation behavior, as shown by the product ion spectrum of the doubly deprotonated U(2'OMeA)UU ( $m/z$  598.60) in Figure 2a. Although the first and third phosphodiester groups dissociate into RNA typical  $y$ - and  $c$ -type ions, no evidence for a preferred dissociation pathway of the second phosphodiester group was found, and all of the theoretically possible fragment ions were observed with similar abundance. This experiment shows that the fragmentation mechanism of RNA is not exclusively influenced by the stabilization of the  $N$ -glycosidic bond





**Figure 2.** (a) Product ion spectrum of the doubly deprotonated modified tetranucleotide U(2'-OMeA)UU with  $m/z$  598.60. The spectrum gives no evidence of a preferred dissociation pathway. (b) Product ion spectrum of doubly deprotonated U(2'-FluoroA)UG with  $m/z$  612.11. The  $a_2$  fragment ion ( $m/z$  556.10) is overlapped by the very abundant  $[M-2H-HB(U)]^{2-}$  ion.

deprotonation of the 2'-hydroxyl group could still be accomplished by intramolecular proton transfer to the adjacent 3'-nucleobase. Deprotonation of the 2'-hydroxyl group would be followed by transesterification, in which the 2'-oxygen participates as a nucleophile, generating a cyclic transition-state. Bond rearrangement and protonation of the leaving group (y ion) by the protonated nucleobase would finally result in cleavage of the phosphodiester backbone and in the formation of the c- and its complementary y-type fragment ions (Scheme 2b).


To verify such an alternative mechanism the tetranucleotide UA(dSpacer)G, incorporating a deoxy building block lacking the nucleobase (Scheme 1), has been subjected to CID. Incorporation of the dSpacer into the sequence enables evaluation of the role of the

nucleobase in the dissociation of the phosphodiester backbone, because the dSpacer does not provide any nucleobase, which could potentially act as an acceptor for the 2'-hydroxyl proton. If the nucleobases were involved in the dissociation of RNA (e.g., as protonation sites), the presence of a building block lacking the nucleobase would block such mechanism. The altered fragmentation pathway should result in a product ion pattern that differs from the one observed for RNA. If, on the other hand, the nucleobase was not involved in the mechanism, dissociation of the phosphodiester backbone would not be affected by the dSpacer and c- and y-type ions would be formed predominantly.

Figure 3 shows an enlarged section of the product ion spectrum of the doubly deprotonated tetranucleotide UA(dSpacer)G with  $m/z$  548.11. It represents the fragment ions generated by cleavage of the precursor between the second ribonucleotide (A) and the dSpacer. The RNA typical  $y_2$  fragment ion ( $m/z$  462.12) was observed with high abundance, whereas all alternative 3'-terminal fragment ions ( $x_2$ ,  $z_2$ , and  $w_2$ ) were of significantly decreased abundance, only reaching about 10-30% of the intensity of the  $y_2$  ion. Likewise,  $c_2$  ( $m/z$  634.09) was the most abundant 5'-terminal fragment ion. The product ion spectrum of the unmodified oligoribonucleotide UAUU (Figure 1b) and the spectrum of the modified sequence incorporating the dSpacer (Figure 3) both show similar fragment ion patterns with the y- and c-type ions as the most abundant fragments. The fragment ion pattern is independent of the presence of the nucleobase. Consequently, the nucleobase does not have any significant influence on the dissociation mechanism of oligoribonucleotides. An alternative mechanism, in which the nucleobase plays a key role as acceptor of the 2'-hydroxyl proton, can be eliminated. These experiments clarify the role the nucleobases are playing in the fragmentation mechanism of oligoribonucleotides and confirm the previously proposed dissociation mechanism of RNA [26], which suggests backbone dissociation to be initiated by formation of an intramolecular cyclic transition-state with the 2'-hydroxyl proton bridged to the 5'-phosphate oxygen (Scheme 2a), while the adjacent nucleobase is not involved.

## Conclusions


Investigation of oligoribonucleotides and their analogs by tandem mass spectrometry establishes the importance of the 2'-hydroxyl substituent as the structural key element in the fragmentation mechanism of RNA. In contrast to DNA, which predominantly fragment into [a-base]- and w-type ions, the presence of the 2'-hydroxyl group of RNA results in formation of abundant c- and y-type ions. The electron-withdrawing 2'-substituent induces a stabilizing effect on the N-glycosidic bond, thus, rendering nucleobase loss less prominent. In addition, the availability of a proton in



**Scheme 2.** Dissociation mechanisms of RNA. (a) Previously proposed mechanism describing the dissociation of RNA. (b) Alternative dissociation mechanism similar to the one known for backbone cleavage of oligoribonucleotides in solution. Both mechanisms include the 2'-hydroxyl proton and lead to the RNA-typical fragment ions. In contrast to the mechanism (a), the alternative mechanism (b) does involve the nucleobase.

the vicinity of the phosphate group is mandatory for the RNA typical backbone cleavage.

Experiments on oligoribonucleotides incorporating the dSpacer, a nucleotide lacking the nucleobase,



**Figure 3.** Product ion spectrum of the doubly deprotonated UA(dSpacer)G ( $m/z$  548.11), which incorporates a building block lacking the nucleobase. The spectrum predominantly shows the RNA characteristic  $y_2$  ion with  $m/z$  462.12. Other fragments indicate backbone cleavage at alternative positions.

showed that gas-phase dissociation of the RNA backbone is not influenced by the nucleobases. Therefore, a mechanism similar to the one known for backbone cleavage of oligoribonucleotides in solution can be eliminated. The results support the mechanism in which backbone dissociation is initiated by formation of an intramolecular cyclic transition-state with the 2'-hydroxyl proton bridged to the 5'-phosphate oxygen.

Results provide fundamental information on the gas-phase dissociation of oligoribonucleotides. This information is needed to provide the basis for reliable tandem mass spectrometric sequencing methods, which will greatly facilitate the identification and verification of oligonucleotides and their analogs used for therapeutic applications, as genetic probes or as primers for amplification.

## Acknowledgments

The authors thank the Swiss National Science Foundation and the University of Bern for generous support of this work.

## References

1. Zamecnik, P. C.; Stephenson, M. L. Inhibition of Rous Sarcoma Virus Replication and Cell Transformation by a Specific Oligodeoxynucleotide. *Proc. Natl. Acad. Sci. U.S.A.* **1978**, *75*, 280–284.
2. Stephenson, M. L.; Zamecnik, P. C. Inhibition of Rous sarcoma Viral RNA Translation by a Specific Oligodeoxyribonucleotide. *Proc. Natl. Acad. Sci. U.S.A.* **1978**, *75*, 285–288.
3. Leumann, C. J. DNA Analogues: From Supramolecular Principles to Biological Properties. *Bioorg. Med. Chem.* **2002**, *10*, 841–854.
4. Baker, B. F.; Monia, B. P. Novel Mechanisms for Antisense-Mediated Regulation of Gene Expression. *Biochim. Biophys. Acta* **1999**, *1489*, 3–18.
5. Goodchild, J. Oligonucleotide Therapeutics: 25 Years Agrowing. *Curr. Opin. Mol. Ther.* **2004**, *6*, 120–128.
6. Altmann, K. -H.; Dean, N. M.; Fabbro, D.; Freier, S. M.; Geiger, T.; Häner, R.; Hüskens, D.; Martin, P.; Monia, B. P.; Müller, M.; Natt, F.; Nicklin, P.; Phillips, J.; Piels, U.; Sasmor, H.; Moser, H. E. Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals. *Chimia.* **1996**, *50*, 168–176.
7. Myers, K. J.; Dean, N. M. Sensible Use of Antisense: How to Use Oligonucleotides as Research Tools. *TIPS* **2000**, *21*, 19–23.
8. Campbell, J. M.; Bacon, T. A.; Wickstrom, E. Oligodeoxynucleoside Phosphorothioate Stability in Subcellular Extracts, Culture Media, Sera and Cerebrospinal Fluid. *J. Biochem. Biophys. Methods* **1990**, *20*, 259–267.
9. Stein, C. A.; Tonkinson, J. L.; Yakubov, L. Phosphorothioate Oligodeoxynucleotides-Anti-Sense Inhibitors of Gene Expression? *Pharmacol. Ther.* **1991**, *52*, 365–384.
10. Tang, W.; Zhu, L.; Smith, L. M. Controlling DNA Fragmentation in MALDI-MS by Chemical Modification. *Anal. Chem.* **1997**, *69*, 302–312.
11. Sanger, F.; Nicklen, S.; Coulson, A. R. DNA Sequencing with Chain-Terminating Inhibitors. *Proc. Natl. Acad. Sci. U.S.A.* **1977**, *74*, 5463–5467.
12. Dovichi, N. J.; Zhang, J. How capillary electrophoresis sequenced the human genome. *Angew. Chem. Int. Ed.* **2000**, *39*, 4463–4468.
13. Wan, K. X.; Gross, J.; Hillenkamp, F.; Gross, M. L. Fragmentation Mechanisms of Oligodeoxynucleotides Studied by H/D Exchange and Electrospray Ionization Tandem Mass Spectrometry. *J. Am. Soc. Mass Spectrom.* **2001**, *12*, 193–205.
14. Wang, Z.; Wan, K. X.; Ramanathan, R.; Taylor, J. S.; Gross, M. L. Structure and Fragmentation Mechanisms of Isomeric T-Rich Oligodeoxynucleotides: A Comparison of Four Tandem Mass Spectrometric Methods. *J. Am. Soc. Mass Spectrom.* **1998**, *9*, 683–691.
15. McLuckey, S. A.; Habibi-Goudarzi, S. Decompositions of Multiply Charged Oligonucleotide Anions. *J. Am. Chem. Soc.* **1993**, *115*, 12085–12095.
16. McLuckey, S. A.; Van Berkel, G. J.; Glish, G. L. Tandem Mass Spectrometry of Small, Multiply Charged Oligonucleotides. *J. Am. Soc. Mass Spectrom.* **1992**, *3*, 60–70.
17. Bartlett, M. G.; McCloskey, J. A.; Manalili, S.; Griffey, R. H. The Effect of Backbone Charge on the Collision-Induced Dissociation of Oligonucleotides. *J. Mass Spectrom.* **1996**, *31*, 1277–1283.
18. Wan, K. X.; Gross, M. L. Fragmentation Mechanisms of Oligodeoxynucleotides: Effects of Replacing Phosphates with Methylphosphonates and Thymines with Other Bases in T-Rich Sequences. *J. Am. Soc. Mass Spectrom.* **2001**, *12*, 580–589.
19. Yacyshyn, B. R.; Chey, W. Y.; Goff, J.; Salzberg, B.; Baerg, R.; Buchman, A. L.; Tami, J.; Yu, R.; Gibiansky, E.; Shanahan, W. R. Double Blind, Placebo Controlled Trial of the Remission Inducing and Steroid Sparing Properties of an ICAM-1 Antisense Oligodeoxynucleotide, Alicaforsen (ISIS 2302), in Active Steroid Dependent Crohn's Disease. *Gut* **2002**, *51*, 30–36.
20. Sewell, K. L.; Geary, R. S.; Baker, B. F.; Glover, J. M.; Mant, T. G.; Yu, R. Z.; Tami, J. A.; Dorr, A. Phase I Trial of ISIS 104838, a 2'-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor- $\alpha$ . *JPET* **2002**, *303*, 1334–1343.
21. Herbst, R. S.; Frankel, S. R. Oblimersen Sodium (Genasense bcl-2 Antisense Oligonucleotide): A Rational Therapeutic to Enhance Apoptosis in Therapy of Lung Cancer. *Clin. Cancer Res.* **2004**, *10*, 4245–4248.
22. Wang, B. H.; Hopkins, C. E.; Belenky, A. B.; Cohen, A. S. Sequencing of Modified Oligonucleotides Using In-Source Fragmentation and Delayed Pulsed Ion Extraction Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. *Int. J. Mass Spectrom. Ion Process* **1997**, *169/170*, 331–350.
23. Sannes-Lowery, K. A.; Hofstadler, S. A. Sequence Confirmation of Modified Oligonucleotides Using IRMPD in the External Ion Reservoir of an Electrospray Ionization Fourier Transform Ion Cyclotron Mass Spectrometer. *J. Am. Soc. Mass Spectrom.* **2003**, *14*, 825–833.
24. Cerny, R. L.; Tomer, K. B.; Gross, M. L.; Grotjahn, L. Fast Atom Bombardment Combined with Tandem Mass Spectrometry for Determining Structures of Small Oligonucleotides. *Anal. Biochem.* **1987**, *165*, 175–182.
25. Kirpekar, F.; Krogh, T. N. RNA Fragmentation Studied in a Matrix-Assisted Laser Desorption/Ionisation Tandem Quadrupole/Orthogonal Time-of-Flight Mass Spectrometer. *Rapid Commun. Mass Spectrom.* **2001**, *15*, 8–14.
26. Schürch, S.; Bernal-Mendez, E.; Leumann, C. J. Electrospray Tandem Mass Spectrometry of Mixed-Sequence RNA/DNA Oligonucleotides. *J. Am. Soc. Mass Spectrom.* **2002**, *13*, 936–945.
27. Nordhoff, E.; Cramer, R.; Karas, M.; Hillenkamp, F.; Kirpekar, F.; Kristiansen, K.; Roepstorff, P. Ion Stability of Nucleic Acids in Infrared Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. *Nucleic Acids Res.* **1993**, *21*, 3347–3357.
28. Ni, J.; Pomerantz, S. C.; Rozenski, J.; Zhang, Y.; McCloskey, J. A. Interpretation of Oligonucleotide Mass Spectra for Determination of Sequence Using Electrospray Ionization and Tandem Mass Spectrometry. *Anal. Chem.* **1996**, *68*, 1989–1999.